NCT05101070 2026-03-18
aCCeleR8-001
Shionogi Inc.
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT03313778 2026-03-04
KEYNOTE-603
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT07415031 2026-02-17
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Not yet recruiting
NCT03917381 2026-02-11
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT07158918 2025-09-08
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
Phase 1/2 Recruiting
NCT04123366 2025-03-17
MK-7339-007
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT05996445 2024-08-23
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
Phase 1 Terminated
NCT02587962 2021-01-14
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Medivir
Phase 1/2 Terminated